Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice

SungJae Shin, Won Shin Seung, Lan Kang Mi, Yong Lee Deog, Moon Sik Yang, Yong Suk Jang, Sang Yoo Han

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We previously induced protective immune response by oral immunization with yeast expressing the ApxIIA antigen. The ApxI antigen is also an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p > 0.01). The highest systemic (IgG) and local (IgA) humoral immune responses to ApxIA and ApxIIA were detected in group E after the third immunization (p > 0.05). The levels of IL-1β and IL-6 after challenge with an A. pleuropneumoniae field isolate did not change significantly in the vaccinated groups. The level of TNF-α increased in a time-dependent manner in group E but was not significantly different after the challenge. After the challenge, the mice in group E had a significantly lower infectious burden and a higher level of protection than the mice in the other groups (p < 0.05). The survival rate in each group was closely correlated to the immune response and histopathological observations in the lung following the challenge. These results suggested that immunity to the ApxIA antigen is required for optimal protection.

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalJournal of Veterinary Science
Volume8
Issue number4
Publication statusPublished - 2007 Dec 1

Fingerprint

Actinobacillus pleuropneumoniae
oral vaccination
Saccharomyces cerevisiae
Vaccination
immune response
antigens
Antigens
Immunization
mice
Actinobacillus pleuropneumoniae 5
Immunity
Immunoglobulin G
immunity
Yeasts
survival rate
yeasts
interleukin-1
Humoral Immunity
Interleukin-1
humoral immunity

All Science Journal Classification (ASJC) codes

  • veterinary(all)

Cite this

Shin, SungJae ; Seung, Won Shin ; Mi, Lan Kang ; Deog, Yong Lee ; Yang, Moon Sik ; Jang, Yong Suk ; Han, Sang Yoo. / Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. In: Journal of Veterinary Science. 2007 ; Vol. 8, No. 4. pp. 383-392.
@article{01c6284db6b84e57989cd479aa173784,
title = "Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice",
abstract = "We previously induced protective immune response by oral immunization with yeast expressing the ApxIIA antigen. The ApxI antigen is also an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p > 0.01). The highest systemic (IgG) and local (IgA) humoral immune responses to ApxIA and ApxIIA were detected in group E after the third immunization (p > 0.05). The levels of IL-1β and IL-6 after challenge with an A. pleuropneumoniae field isolate did not change significantly in the vaccinated groups. The level of TNF-α increased in a time-dependent manner in group E but was not significantly different after the challenge. After the challenge, the mice in group E had a significantly lower infectious burden and a higher level of protection than the mice in the other groups (p < 0.05). The survival rate in each group was closely correlated to the immune response and histopathological observations in the lung following the challenge. These results suggested that immunity to the ApxIA antigen is required for optimal protection.",
author = "SungJae Shin and Seung, {Won Shin} and Mi, {Lan Kang} and Deog, {Yong Lee} and Yang, {Moon Sik} and Jang, {Yong Suk} and Han, {Sang Yoo}",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "383--392",
journal = "Journal of Veterinary Science",
issn = "1229-845X",
publisher = "Korean Society of Veterinary Science",
number = "4",

}

Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. / Shin, SungJae; Seung, Won Shin; Mi, Lan Kang; Deog, Yong Lee; Yang, Moon Sik; Jang, Yong Suk; Han, Sang Yoo.

In: Journal of Veterinary Science, Vol. 8, No. 4, 01.12.2007, p. 383-392.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice

AU - Shin, SungJae

AU - Seung, Won Shin

AU - Mi, Lan Kang

AU - Deog, Yong Lee

AU - Yang, Moon Sik

AU - Jang, Yong Suk

AU - Han, Sang Yoo

PY - 2007/12/1

Y1 - 2007/12/1

N2 - We previously induced protective immune response by oral immunization with yeast expressing the ApxIIA antigen. The ApxI antigen is also an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p > 0.01). The highest systemic (IgG) and local (IgA) humoral immune responses to ApxIA and ApxIIA were detected in group E after the third immunization (p > 0.05). The levels of IL-1β and IL-6 after challenge with an A. pleuropneumoniae field isolate did not change significantly in the vaccinated groups. The level of TNF-α increased in a time-dependent manner in group E but was not significantly different after the challenge. After the challenge, the mice in group E had a significantly lower infectious burden and a higher level of protection than the mice in the other groups (p < 0.05). The survival rate in each group was closely correlated to the immune response and histopathological observations in the lung following the challenge. These results suggested that immunity to the ApxIA antigen is required for optimal protection.

AB - We previously induced protective immune response by oral immunization with yeast expressing the ApxIIA antigen. The ApxI antigen is also an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p > 0.01). The highest systemic (IgG) and local (IgA) humoral immune responses to ApxIA and ApxIIA were detected in group E after the third immunization (p > 0.05). The levels of IL-1β and IL-6 after challenge with an A. pleuropneumoniae field isolate did not change significantly in the vaccinated groups. The level of TNF-α increased in a time-dependent manner in group E but was not significantly different after the challenge. After the challenge, the mice in group E had a significantly lower infectious burden and a higher level of protection than the mice in the other groups (p < 0.05). The survival rate in each group was closely correlated to the immune response and histopathological observations in the lung following the challenge. These results suggested that immunity to the ApxIA antigen is required for optimal protection.

UR - http://www.scopus.com/inward/record.url?scp=37349038473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349038473&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 383

EP - 392

JO - Journal of Veterinary Science

JF - Journal of Veterinary Science

SN - 1229-845X

IS - 4

ER -